Granulosa cell tumor of the ovary - Retrospective analysis of 45 cases

Basit Öğe Kaydı
dc.authorwosidBasaran, Mert/AAT-7762-2020
dc.authorwosidTas, Faruk/AAF-8751-2019
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.contributor.authorUygun, K
dc.contributor.authorAydiner, A
dc.contributor.authorSaip, P
dc.contributor.authorBasaran, M
dc.contributor.authorTas, F
dc.contributor.authorKocak, Z
dc.contributor.authorDincer, M
dc.date.accessioned2024-06-12T11:02:48Z
dc.date.available2024-06-12T11:02:48Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAdult granulosa cell tumors of the ovary are rare neoplasms, accounting for less than 5% of all ovarian malignancies. In addition to the tumor stage, residual disease, patient age, tumor size, extent of surgery, and also some histologic factors have been reported to be of prognostic importance. Tumor registries were screened for all patients treated between 1979 and 1998 for ovarian tumors at the University of Istanbul. There were 952 ovarian carcinomas, of which 47 were granulosa cell tumors. All charts were reviewed, and the clinical data were extracted. Prognostic factors and treatment results were evaluated retrospectively. The median follow-up was 84 (range: 6-141 months) months. According to univariate analysis, there were only two significant factors for overall survival (OS): stage and presence of residual disease. The OS of the 23 patients with early stage (mean, 122 months; median, unreached) was significantly (p = 0.0001) better than the OS of the 22 patients with advanced stage (mean, 34 months; median, 21 months). A significant difference (p = 0.0004) in OS was also observed between patients with residual (mean, 42 months; median, 21 months) and nonresidual (mean, 108 months; median, unreached) disease. In a multivariate analysis, only stage remained statistically significant (p = 0.0001). The overall 5-year survival rate was 55% and median survival after recurrence was 21 months. Despite the small number of patients, the study showed that stage and macroscopic residual disease are significant prognostic factors. The benefit of chemotherapy and radiotherapy remains controversial.en_US
dc.identifier.doi10.1097/01.coc.0000037918.88451.6A
dc.identifier.endpage521en_US
dc.identifier.issn0277-3732
dc.identifier.issn1537-453X
dc.identifier.issue5en_US
dc.identifier.pmid14528083en_US
dc.identifier.scopus2-s2.0-0141891977en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage517en_US
dc.identifier.urihttps://doi.org/10.1097/01.coc.0000037918.88451.6A
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21417
dc.identifier.volume26en_US
dc.identifier.wosWOS:000185829500018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAmerican Journal Of Clinical Oncology-Cancer Clinical Trialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGranulosa Cell Tumoren_US
dc.subjectOvaryen_US
dc.subjectPrognostic Factorsen_US
dc.subjectSurvivalen_US
dc.titleGranulosa cell tumor of the ovary - Retrospective analysis of 45 casesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu